CAT Clinical Trial Update

Cambridge Antibody Tech Group PLC
17 June 2003


03/CAT/15

FOR IMMEDIATE RELEASE

14.00 BST, 09.00 EST,  Tuesday 17 June 2003


For further information contact:
Cambridge Antibody Technology                      Weber Shandwick Square Mile (Europe)
Tel: [phone]                          Tel: [phone]
John Aston, Chief Financial Officer                Rachel Lankester
Rowena Gardner, Director of Corporate              Kevin Smith
Communications
                                                   BMC Communications/The Trout Group (USA)
                                                   Tel: [phone]
                                                   Brad Miles, ext 17 (media)
                                                   Brandon Lewis, ext.15 (investors)



CAMBRIDGE ANTIBODY TECHNOLOGY REPORTS COMPLETION OF ENROLMENT IN EUROPEAN PHASE
II/III TRIAL OF TRABIO(TM) IN GLAUCOMA SURGERY

Cambridge, UK...  Cambridge Antibody Technology (LSE: CAT; NASDAQ: CATG)
today announces the completion of enrolment in its Phase II/III European
clinical trial of TrabioTM, a human monoclonal antibody being developed as an
anti-scarring agent to improve the outcome of glaucoma filtration surgery. In
this trial, 344 patients undergoing first time trabeculectomy have been enrolled
at major eye hospitals in six countries. Data are expected to be available
towards the end of 2004.

Recruitment continues in the US clinical trial and in the International Phase
III clinical trial of Trabio.

- ENDS -

Notes to Editors

Cambridge Antibody Technology (CAT):

•  CAT is a UK-based biotechnology company using its proprietary
technologies and capabilities in human monoclonal antibodies for drug discovery
and drug development. Based near Cambridge, England, CAT currently employs
around 270 people.

•  CAT is a leader in the discovery and development of human therapeutic
antibodies and has an advanced proprietary platform technology for rapidly
isolating human monoclonal antibodies using phage display systems. CAT has
extensive phage antibody libraries, currently incorporating more than 100
billion distinct antibodies. These libraries form the basis for the Company's 
strategy to develop a portfolio of antibody-based drugs.

•  HumiraTM, the leading CAT-derived antibody, isolated and optimised in
collaboration with Abbott, has been approved by the US Food and Drug
Administration for marketing in the US as a treatment for rheumatoid arthritis.
Six further CAT-derived human therapeutic antibodies are at various stages of
clinical trials..

•  CAT has alliances with a large number of pharmaceutical and biotechnology
companies to discover, develop and commercialise human monoclonal antibody-based
products. CAT has also licensed its proprietary human phage antibody libraries
to several companies for target validation and drug discovery. CAT's
collaborators include: Abbott, Amgen, Amrad, Chugai, Elan, Genzyme, Human Genome
Sciences, Merck & Co, Pfizer and Wyeth Research.

•  CAT is listed on the London Stock Exchange and on NASDAQ since June
2001. CAT raised £41m in its IPO in March 1997 and £93m in a secondary offering
in March 2000.

Trabio:

•  Trabio (lerdelimumab, CAT-152) is a human anti-TGFB2 monoclonal antibody
which is in development as an anti-scarring agent, particularly following eye
surgery.

•  Glaucoma is a group of eye conditions in which the optic nerve is
permanently damaged at the point where it leaves the eye, resulting in
significant loss of vision or blindness. The major cause of the damage is
thought to be raised presssure inside the eye.

•  Trabeculectomy is the commonest type of surgical operation performed on
patients with glaucoma to lower intraocular pressure.  The major reason for this
surgical operation to fail to achieve the desired effects is the excessive
scarring that can occur.

•  CAT estimates that up to 250,000 patients per year undergoing an
operation for glaucoma in the US and Western Europe could potentially benefit
from treatment with Trabio.

•  Discussions continue with a number of potential partners with a view to
the marketing and selliing of Trabio


Application of the Safe Harbor of the Private Securities Litigation Reform Act
of 1995:

This press release contains statements about Cambridge Antibody Technology Group
plc ("CAT") that are forward looking statements. All statements other than
statements of historical facts included in this press release may be forward
looking statements within the meaning of Section 21E of the Securities Exchange
Act of 1934. These forward looking statements are based on numerous assumptions
regarding CAT's present and future business strategies and the
environment in which CAT will operate in the future. Certain factors that could
cause CAT's actual results, performance or achievements to differ
materially from those in the forward looking statements include: market
conditions, CAT's ability to enter into and maintain collaborative
arrangements, success of product candidates in clinical trials, regulatory
developments and competition.


                      This information is provided by RNS
            The company news service from the London Stock Exchange